News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Frank Worden, MD

Articles by Frank Worden, MD

Treating BRAF V600 and NTRK Gene Fusion Positivity

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

The Future of RAI-Refractory DTC Management

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

Rationale for Sequencing in Second Line

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

Advice for Managing RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

Molecular Testing in Treatment Selection

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

Sorafenib and Lenvatinib Side Effect Profile and Dosing

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

Multidisciplinary Management for the Treatment of DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Approaching Treatment of Low-Volume DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Understanding Sequencing and What to Look for in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Roles and Communication in Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

Management of DTC in Clinical Practice

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

Discussing Iodine-Refractory DTC With Patients

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

Clinical Scenarios to Consider for RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

Thyrotropin Suppression as DTC Treatment Option

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

Role of Radioiodine Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

DTC: Histological Subtypes and Tumor Differentiation

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

Differentiated Thyroid Cancer: Increasing Incidence

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

Latest Updated Articles

Understanding Sequencing and What to Look for in DTC
Published: January 18th 2021 | Updated:
$RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT$
RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT
Published: January 21st 2021 | Updated:
Treating BRAF V600 and NTRK Gene Fusion Positivity
Published: February 11th 2021 | Updated:
$Advice for Managing RAI-Refractory DTC$
Advice for Managing RAI-Refractory DTC
Published: January 28th 2021 | Updated:
Thyrotropin Suppression as DTC Treatment Option
Published: December 21st 2020 | Updated:
Sorafenib and Lenvatinib Side Effect Profile and Dosing
Published: January 21st 2021 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma